Aldehydic agents for allosteric modification of hemoglobin
    1.
    发明授权
    Aldehydic agents for allosteric modification of hemoglobin 失效
    用于血红蛋白变构修饰的醛类药物

    公开(公告)号:US5599974A

    公开(公告)日:1997-02-04

    申请号:US308805

    申请日:1994-09-19

    IPC分类号: C07C65/30 C07C69/86 C07C51/42

    摘要: Chemical compounds which interact inside the central water cavity of hemoglobin and bridge between the two .alpha. subunits can be used to allosterically modify hemoglobin towards tense and relaxed states. The functional groups employed are aldehydes and carboxylic acids, wherein the aldehydes form covalent bonds (schiff base) with amino acid residues of hemoglobin and the carboxylic acids form ionic bonds with amino acid residues of hemoglobin. Particularly useful compounds within the practice of this invention bond to the n-terminal valine of one .alpha. subunit of hemoglobin, and the lysine 99 and/or arginine 141 of the other .alpha. subunit.

    摘要翻译: 在血红蛋白的中心水腔和两个α亚基之间的桥梁之间相互作用的化学化合物可用于将血红蛋白改变为变态和松弛状态。 所使用的官能团是醛和羧酸,其中醛与血红蛋白的氨基酸残基形成共价键(席夫碱),羧酸与血红蛋白的氨基酸残基形成离子键。 在本发明实践中特别有用的化合物与血红蛋白的一个α亚基的n末端缬氨酸结合,另一个α亚基的赖氨酸99和/或精氨酸141结合。

    Anti-sickling agents
    4.
    发明申请
    Anti-sickling agents 有权
    防蛀剂

    公开(公告)号:US20050209199A1

    公开(公告)日:2005-09-22

    申请号:US11078690

    申请日:2005-03-14

    CPC分类号: C07D307/46 C07D417/04

    摘要: Compounds for the treatment of sickle-cell disease, and methods for their use are provided. The compounds have a dual mode of action. First, binding of the compounds to hemoglobin increases the oxygen affinity of both normal and sickle hemoglobin. Secondly, binding of these compounds to the N-terminal amino acid of sickle hemoglobin results in destabilization of potential contacts between sickle hemoglobin molecules, preventing polymerization and the formation of fibrous precipitates of the sickle hemoglobin. The compounds are also useful for inducing hypoxia, e.g. to augment cancer treatments.

    摘要翻译: 提供了治疗镰状细胞病的化合物及其使用方法。 这些化合物具有双重作用模式。 首先,化合物与血红蛋白的结合增加了正常和镰状血红蛋白的氧亲和力。 其次,这些化合物与镰刀血红蛋白的N-末端氨基酸的结合导致镰刀血红蛋白分子之间的潜在接触不稳定,防止聚合和镰状血红蛋白的纤维沉淀物的形成。 这些化合物也可用于诱导缺氧,例如, 增加癌症治疗。

    Anti-sickling agents
    6.
    发明授权
    Anti-sickling agents 有权
    防蛀剂

    公开(公告)号:US07119208B2

    公开(公告)日:2006-10-10

    申请号:US11078690

    申请日:2005-03-14

    CPC分类号: C07D307/46 C07D417/04

    摘要: Compounds for the treatment of sickle-cell disease, and methods for their use are provided. The compounds have a dual mode of action. First, binding of the compounds to hemoglobin increases the oxygen affinity of both normal and sickle hemoglobin. Secondly, binding of these compounds to the N-terminal amino acid of sickle hemoglobin results in destabilization of potential contacts between sickle hemoglobin molecules, preventing polymerization and the formation of fibrous precipitates of the sickle hemoglobin. The compounds are also useful for inducing hypoxia, e.g. to augment cancer treatments.

    摘要翻译: 提供了治疗镰状细胞病的化合物及其使用方法。 这些化合物具有双重作用模式。 首先,化合物与血红蛋白的结合增加了正常和镰状血红蛋白的氧亲和力。 其次,这些化合物与镰刀血红蛋白的N-末端氨基酸的结合导致镰刀血红蛋白分子之间的潜在接触不稳定,防止聚合和镰状血红蛋白的纤维沉淀物的形成。 这些化合物也可用于诱导缺氧,例如, 增加癌症治疗。